Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with recurrent or metastatic nasopharyngeal carcinoma (cancer of the back of the nose/throat that has come back or spread)
• People whose cancer has been confirmed by a tissue sample as a specific type of nasopharyngeal carcinoma (WHO Type II or III)
• People who have a good general level of physical functioning, able to carry out normal daily activities with little or no limitation (ECOG score of 0 or 1)
• People who have not yet received any treatment — such as radiotherapy, chemotherapy, immunotherapy, or biological therapy — for their recurrent or metastatic nasopharyngeal carcinoma
• People who have no medical reasons preventing them from receiving immunotherapy or chemoradiotherapy
• People who have at least one tumour that doctors determine can safely be treated with a focused type of radiation called SBRT
• People who have at least one tumour that can be measured using standard imaging criteria (RECIST v1.1)
• People whose blood counts are within an acceptable range, indicating the bone marrow is functioning adequately (confirm with trial site for specific values)
• People whose liver function test results are within acceptable limits (confirm with trial site for specific values)
• People whose kidney function results are within acceptable limits (confirm with trial site for specific values)
• People who agree to use effective contraception during treatment and for three months after treatment ends
• People who have been fully informed about the nature of the study and have signed a written consent form

Who may not be able to join:

• People with a known allergy to monoclonal antibodies, any component of PD-1 antibody medicines, or the chemotherapy drugs gemcitabine or cisplatin
• People who have an unexplained fever above 38.5°C that is not related to the tumour itself
• People who have an active autoimmune disease — a condition where the immune system attacks the body's own tissues (for example, certain eye, gut, liver, kidney, thyroid, or blood vessel conditions, or asthma requiring specific inhaler treatment)
• People with a known history of HIV, active Hepatitis B, or positive Hepatitis C antibody results
• People with significant heart problems, including severe heart failure (NYHA class 3 or 4), unstable chest pain, a heart attack within the past year, or a serious irregular heartbeat requiring treatment
• People who are pregnant or breastfeeding
• People who have had another cancer in the past, except for certain treated skin cancers, early-stage cervical cancer, or a specific low-risk type of thyroid cancer
• People who have received a live vaccine within 30 days before the planned start of the study
• People with a psychiatric condition or substance use disorder that could interfere with their ability to take part in the study
• People with any other condition — including mental health concerns or personal/social circumstances — that, in the doctor's judgement, could affect the person's ability to participate or affect the reliability of the study results

Important: Always verify eligibility with the trial site directly before applying.